ANAVIP—a F(ab’)2 antivenom designed to circulate for weeks5

F(ab’)2 antivenom and single Fab antivenom have fundamental PK differences1,3,4

Image module

ANAVIP—a PK profile optimized to match North American rattlesnake venom1,3,4

  • Elimination half-life for ANAVIP is 5.5 days, compared with <1 day with a single Fab antivenom5,6
  • A difference in half-life has been attributed to molecular mass4,7
    • Unbound antivenom <70 kDa is more likely to be eliminated renally3

ANAVIP has distinct PK advantages over a single Fab antivenom4-6


Important Safety Information

ANAVIP® [Crotalidae Immune F(ab’)2 (Equine)] is an equine-derived antivenin indicated for the management of adult and pediatric patients with North American rattlesnake envenomation.




The most common adverse reactions observed in more than 2 percent of patients in the clinical trials for ANAVIP were: pruritus, nausea, rash, arthralgia, peripheral edema, erythema, headache, myalgia, pain in extremity, and vomiting.


ANAVIP may cause allergic reactions.

Patients with known allergies to horse protein are particularly at risk for an anaphylactic reaction. If signs or symptoms of anaphylaxis or hypersensitivity reactions (including urticaria, rash, tightness of the chest, wheezing, hypotension) occur, discontinue immediately and institute appropriate treatment.

Monitor patients with follow-up visits for signs and symptoms of delayed allergic reactions or serum sickness (rash, fever, myalgia, arthralgia, pruritus, urticarial rash) and treat appropriately if necessary.

Transmissible Infectious Agents
ANAVIP is made from equine (horse) plasma and may therefore carry a risk of transmitting infectious agents, e.g., viruses.

Reactions to Cresol
Trace amounts of cresol from the manufacturing process are contained in ANAVIP. Localized reactions and generalized myalgias have been reported with the use of cresol as an injectable excipient.

See Full Prescribing Information